UPB (Upstream Bio) PEG Ratio : N/A (As of Apr. 06, 2025)

View and export this data going back to 2024. Start your Free Trial

What is Upstream Bio PEG Ratio?

PE Ratio without NRI / 5-Year EBITDA Growth Rate*

PEG Ratio is defined as the PE Ratio without NRI divided by the growth ratio. The growth rate we use is the 5-Year EBITDA growth rate. As of today, Upstream Bio's PE Ratio without NRI is 0.00. Upstream Bio's 5-Year EBITDA growth rate is 0.00%. Therefore, Upstream Bio's PEG Ratio for today is N/A.

* The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.

The historical rank and industry rank for Upstream Bio's PEG Ratio or its related term are showing as below:

UPB's PEG Ratio is not ranked ^*
in the Biotechnology industry.
Industry Median: 1.36
* Ranked among companies with meaningful PEG Ratio only.

Peter Lynch thinks a company with a P/E ratio equal to its growth rate is fairly valued.

Upstream Bio PEG Ratio Historical Data

The historical data trend for Upstream Bio's PEG Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Upstream Bio PEG Ratio Chart

Upstream Bio Annual Data

Trend

Dec22

Dec23

Dec24

PEG Ratio

Upstream Bio Quarterly Data
	Dec22	Jun23	Sep23	Dec23	Jun24	Sep24	Dec24
PEG Ratio	Get a 7-Day Free Trial			-	-	-	-	-

Competitive Comparison of Upstream Bio's PEG Ratio

For the Biotechnology subindustry, Upstream Bio's PEG Ratio, along with its competitors' market caps and PEG Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Upstream Bio's PEG Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Upstream Bio's PEG Ratio distribution charts can be found below:

* The bar in red indicates where Upstream Bio's PEG Ratio falls into.

Save Embed

;

Save Embed

;

Upstream Bio PEG Ratio Calculation

PEG Ratio is defined as the PE Ratio without NRI divided by the growth ratio. The ratio we use is the 5-Year EBITDA growth rate.

Upstream Bio's PEG Ratio for today is calculated as

PEG Ratio	=	PE Ratio without NRI	/	5-Year EBITDA Growth Rate*
	=		/	0.00
	=	N/A

* Note: The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.

Upstream Bio (NAS:UPB) PEG Ratio Explanation

To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the P/E ratio divided by the growth ratio. He thinks a company with a P/E ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a P/E of 20, instead of a company growing 10% a year with a P/E of 10.

Upstream Bio PEG Ratio Related Terms

Thank you for viewing the detailed overview of Upstream Bio's PEG Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.

Upstream Bio Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Upstream Bio Inc (NAS:UPB) » Definitions » PEG Ratio

Comparable Companies

Traded in Other Exchanges

N/A

Address

890 Winter Street, Suite 200, Waltham, MA, USA, 02451

Website

https://www.upstreambio.com

Upstream Bio Inc is a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. It is developing verekitug, the known antagonist currently in clinical development that targets the receptor for Thymic Stromal Lymphopoietin (TSLP), a cytokine that is a clinically validated driver of inflammatory response positioned upstream of multiple signaling cascades that affect a variety of immune-mediated diseases.